Patients with HIV infection are at increased risk of cardiovascular disease (CVD). Vitamin D insufficiency has been associated with increased CVD risk in non-HIV populations. This study sought to determine the relationship between vitamin D status and markers of CVD and HIV-related factors in HIV-positive patients.
Methods
Patients with HIV infection on antiretroviral therapy and healthy controls were prospectively enrolled. Fasting lipids, glucose, insulin, inflammatory markers (soluble tumour necrosis factor-α receptor I, interleukin-6 and high-sensitivity C-reactive protein) and endothelial markers (soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1) were measured. Fasting 25-hydroxyvitamin D (25(OH)D) was measured from stored serum samples. The internal carotid artery and common carotid artery (CCA) intima-media thickness (IMT) were measured in a subset of HIV-positive patients. Baseline cross-sectional data were analysed.
Results
A total of 149 HIV-positive patients (56 with carotid IMT) and 34 controls were included. Controls had higher adjusted mean 25(OH)D levels than HIV-positive patients (P=0.02). In multivariable linear regression among the HIV-positive patients, 25(OH)D was positively associated with CD4+ T-cell restoration after antiretroviral therapy (ΔCD4 = current - nadir CD4+ T-cell; P<0.01), but was not associated with inflammatory or endothelial markers. In multivariable logistic regression, odds of having CCA IMT above the median were more than 10x higher in those with lower 25(OH)D levels (OR=10.62, 95% CI 1.37-82.34; P<0.01).
Conclusions
Vitamin D status in HIV-positive patients was positively associated with improved immune restoration after antiretroviral therapy and negatively associated with CCA IMT. These findings suggest that vitamin D may play a role in HIV-related CVD and in immune reconstitution after antiretroviral therapy.
References
1.
TriantV.A., LeeH., HadiganC., GrinspoonS.K.Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab2007; 92: 2506–2512.
2.
McComseyG.A., O'RiordanM., HazenS.L.Increased carotid intima media thickness and cardiac biomarkers in HIV infected children. AIDS2007; 21: 921–927.
3.
RossA.C., ArmentroutR., O'RiordanM.A.Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy and lipoatrophy. J Acquir Immune Defic Syndr2008; 49: 499–506.
4.
TorrianiF.J., KomarowL., ParkerR.A.Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: the ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol2008; 52: 569–576.
5.
KullerL.H., TracyR., BellosoW.Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med2008; 5: e203.
6.
RidkerP.M., RifaiN., PfefferM., SacksF., LepageS., BraunwaldE.Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation2000; 101: 2149–2153.
7.
PaiJ.K., PischonT., MaJ.Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med2004; 351: 2599–2610.
8.
RidkerP.M., RifaiN., RoseL., BuringJ.E., CookN.R.Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med2002; 347: 1557–1565.
9.
HwangS.J., BallantyneC.M., SharrettA.R.Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation1997; 96: 4219–4225.
10.
ChungN.A., LydakisC., BelgoreF., Li-Saw-HeeF.L., BlannA.D., LipG Y.Angiogenesis, thrombogenesis, endothelial dysfunction and angiographic severity of coronary artery disease. Heart2003; 89: 1411–1415.
11.
DaviesM.J., GordonJ.L., GearingA.J.The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol1993; 171: 223–229.
12.
RossA.C., RizkN., O'RiordanM.A.Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis2009; 49: 1119–1127.
13.
JuddS.E., TangprichaV.Vitamin D deficiency and risk for cardiovascular disease. Am J Med Sci2009; 338: 40–44.
14.
LondonG.M., GuerinA.P., VerbekeF.H.Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol2007; 18: 613–620.
15.
TargherG., BertoliniL., PadovaniR.Serum 25-hydroxyvitamin D3 concentrations and carotid artery intima-media thickness among type 2 diabetic patients. Clin Endocrinol (Oxf)2006; 65: 593–597.
16.
WangT.J., PencinaM.J., BoothS.L.Vitamin D deficiency and risk of cardiovascular disease. Circulation2008; 117: 503–511.
17.
SchleithoffS.S., ZittermannA., TenderichG., BertholdH.K., StehleP., KoerferR.Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr2006; 83: 754–759.
18.
RahmanA., HersheyS., AhmedS., NibbelinkK., SimpsonR.U.Heart extracellular matrix gene expression profile in the vitamin D receptor knockout mice. J Steroid Biochem Mol Biol2007; 103: 416–419.
19.
TishkoffD.X., NibbelinkK.A., HolmbergK.H., DanduL., SimpsonR.U.Functional vitamin D receptor (VDR) in the t-tubules of cardiac myocytes: VDR knockout cardiomyocyte contractility. Endocrinology2008; 149: 558–564.
20.
SimpsonR.U., HersheyS.H., NibbelinkK.A.Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse. J Steroid Biochem Mol Biol2007; 103: 521–524.
21.
LondonG.M., GuerinA.P., VerbekeF.H.Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol2007; 18: 613–620.
22.
LiY.C., QiaoG., UskokovicM., XiangW., ZhengW., KongJ.Vitamin D: a negative endocrine regulator of the renin– angiotensin system and blood pressure. J Steroid Biochem Mol Biol2004; 89–90: 387–392.
23.
KamenD.L., TangprichaV.Vitamin D and molecular actions on the immune system: modulation of innate and autoimmunity. J Mol Med2010; 88: 441–450.
24.
KhazaiN., JuddS.E., TangprichaV.Calcium and vitamin D: skeletal and extraskeletal health. Curr Rheumatol Rep2008; 10: 110–117.
25.
van EttenE., StoffelsK., GysemansC., MathieuC., OverberghL.Regulation of vitamin D homeostasis: implications for the immune system. Nutr Rev2008; 66Suppl 2: S125–S134.
26.
von EssenM.R., KongsbakM., SchjerlingP., OlgaardK., OdumN., GeislerC.Vitamin D controls T cell antigen receptor signaling and activation of human T cells. Nat Immunol2010; 11: 344–349.
27.
MehtaS., GiovannucciE., MugusiF.M.Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality. PLoS ONE2010; 5: e8770.
28.
de LuisD.A., BachillerP., AllerR.[Relation among micronutrient intakes with CD4 count in HIV infected patients]. Nutr Hosp2002; 17: 285–289. Spanish.
29.
ArpadiS.M., McMahonD., AbramsE.J.Effect of bimonthly supplementation with oral cholecalciferol on serum 25-hydroxyvitamin D concentrations in HIV-infected children and adolescents. Pediatrics2009; 123: e121–e126.
30.
MuellerN.J., FuxC.A., LedergerberB.High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS2010; 24: 1127–1134.
31.
RodríguezM., DanielsB., GunawardeneS., RobbinsG.K.High frequency of vitamin D deficiency in ambulatory HIV-positive patients. AIDS Res Hum Retroviruses2009; 25: 9–14.
32.
Van Den Bout-Van Den BeukelC.J., FievezL., MichelsM.Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses2008; 24: 1375–1382.
33.
MatthewsD.R., HoskerJ.P., RudenskiA.S., NaylorB.A., TreacherD.F., TurnerR.C.Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia1985; 28: 412–419.
34.
O'LearyD.H., PolakJ.F., WolfsonS.K.Jr.. Use of sonography to evaluate carotid atherosclerosis in the elderly. The Cardiovascular Health Study. CHS Collaborative Research Group. Stroke1991; 22: 1155–1163.
35.
MartínezE., MilinkovicA., BuiraE.Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area. HIV Med2007; 8: 251–258.
36.
ObelN., ThomsenH.F., KronborgG.Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis2007; 44: 1625–1631.
37.
BrownT.T., QaqishR.B.Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review [see comment]. AIDS2006; 20: 2165–2174.
38.
GiovannucciE.Vitamin D status and cancer incidence and mortality. Adv Exp Med Biol2008; 624: 31–42.
39.
TargherG., BertoliniL., PadovaniR.Serum 25-hydroxyvitamin D3 concentrations and carotid artery intima-media thickness among type 2 diabetic patients. Clin Endocrinol (Oxf)2006; 65: 593–597.
40.
KraśniakA., DrozdzM., PasowiczM.Factors involved in vascular calcification and atherosclerosis in maintenance haemodialysis patients. Nephrol Dial Transplant2007; 22: 515–521.
41.
SchleithoffS.S., ZittermannA., TenderichG., BertholdH.K., StehleP., KoerferR.Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr2006; 83: 754–759.
42.
SheaM.K., BoothS.L., MassaroJ.M.Vitamin K and vitamin D status: associations with inflammatory markers in the Framingham Offspring Study. Am J Epidemiol2008; 167: 313–320.
43.
JordeR., SneveM., TorjesenP.A., FigenschauY., GøranssonL.G., OmdalR.No effect of supplementation with cholecalciferol on cytokines and markers of inflammation in overweight and obese subjects. Cytokine2010; 50: 175–180.
44.
StubbsJ.R., IdicullaA., SlusserJ., MenardR., QuarlesL.D.Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol2010; 21: 353–361.
45.
JaegerP., OttoS., SpeckR.F.Altered parathyroid gland function in severely immunocompromised patients infected with human immunodeficiency virus. J Clin Endocrinol Metab1994; 79: 1701–1705.
46.
HaugC., MullerF., AukrustP., FrolandS.S.Subnormal serum concentration of 1,25-vitamin D in human immunodeficiency virus infection: correlation with degree of immune deficiency and survival. J Infect Dis1994; 169: 889–893.
47.
TeichmannJ., StephanE., LangeU.Osteopenia in HIV-infected women prior to highly active antiretroviral therapy. J Infect2003; 46: 221–227.
48.
BrownT.T., McComseyG.A.Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther2010; 15: 425–429.
49.
CozzolinoM., VidalM., ArcidiaconoM.V., TebasP., YarasheskiK.E., DussoA.S.HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS2003; 17: 513–520.
